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Abstract 
Although the importance of translation for the development of tissue engineering, 
regenerative medicine and cell-based therapies is widely recognised, the process of 
translation is less well understood. This is particularly the case amongst some early career 
researchers (ECRs) who may not appreciate the intricacies of translational research or make 
decisions early in development which later hinders effective translation. Based on our own 
research and experiences as ECRs involved in tissue engineering and regenerative medicine 
(TERM) translation, we discuss common pitfalls associated with translational research, 
providing practical solutions and important considerations which will aid process and product 
development. These suggestions range from effective project management, consideration of 
key manufacturing, clinical and regulatory matters and means of exploiting research for 
successful commercialisation.   
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Introduction  
The development of reimbursable cell therapies, tissue engineered constructs and 
regenerative medicines pose significant technical and commercial challenges. However, 
increasing numbers of therapies are being approved by international regulatory bodies, with 
initial therapies now gaining reimbursement. To accelerate the development of promising 
products in the tissue engineering and regenerative medicine (TERM) field, translational 
research needs to underpin and drive the development process. Translational research, as 
we’ve defined it, is that which takes science from the bench by addressing specific 
technological challenges subsequently enabling the delivery of healthcare and economic 
benefits. As researchers at the forefront of this nascent industry, we have come to realise that 
the process of translation can be intricate, exceptionally resource consuming and vulnerable 
to unexpected obstacles. What follows is a compilation of ‘tips and tricks’ from the 
perspective of early career researchers (ECRs), based on our own experience and research, 
which facilitate translation and will improve the chances of successful product development. 
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1. Manage the research effectively 
Perhaps the most important factor in the translation and development of a TERM therapy, or 
in any project, is its management. Without a clear and detailed research management plan, 
resources may be wasted and deliverables unmet. Outlined below are strategies to adopt in 
the day-to-day running of a translational research project.  
 
1.1 Utilise project management principles 
The success of a project is ultimately based upon diligent planning and execution rather than 
the results achieved; ‘negative’ results can be just as informative as ‘positive’. Dividing 
projects into discrete work packages with clear milestones and deliverables enables resource 
allocation (Section 1.2) and helps in identifying potential bottlenecks and high risk elements 
for which mitigation/contingencies can be planned, for example, obtaining ethical approval 
for human-derived materials, or licensing for in vivo research.  Likewise, key equipment may 
fail, therefore contingencies should be established in the form of service agreements, 
maintenance plans and where possible, alternative providers. Failure to plan ahead in these 
areas can significantly hinder or even halt progress of a project. Risk must be managed by 
anticipating it – risk registers have value.  
 
Comprehensive project planning is essential for successful translation. The project plan is 
best represented by a Gantt chart with a realistic level of detail that can be followed by all 
stakeholders with a personal guideline of one deliverable per research associate per quarter. 
The plan should be prepared and/or reviewed by all stakeholders to ensure all understand and 
believe in it. Translational research is often a high-risk activity and projects do not always 
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progress as planned. It is therefore good discipline as part of the project plan to establish 
phase gates where the conditions for proceeding are clear. If unavoidable delays occur in one 
work package, identify other packages or, at a minimum, sections of a package, which could 
be brought forward. Milestones provide the opportunity to adapt and reassess the project as 
appropriate, and must have associated contingencies, so that if milestones are not achieved 
(e.g. processes are not reproducible, or outcomes predicted from in vitro data are not 
observed in vivo), pre-identified alternatives are investigated. In some situations, it may be 
necessary to terminate projects and/or work packages because they are no longer a good use 
of resource/effort. Where alternative directions for the research are pursued, the reasons for 
doing so must be strategic; the traditional academic approach of ‘I did this because it was 
more interesting’ is not acceptable in a translational setting.  
 
Understanding project management tools as used in large companies for large projects is an 
important part of training, professional development and understanding the environment. It is 
worth noting, however, that for smaller projects in an academic setting, their full 
implementation can be overkill and recognising how to tailor these tools to achieve the 
desired outcome is equally important.  
 
1.2 Prepare for day-to-day as well as long-term working 
Effective project management should also account for the resources required for each 
experiment. Prior to experimentation, ensure sufficient quantities of consumables/reagents 
are in stock, and note which require advance preparation (e.g. thawing, sterilizing). Reserve 
necessary equipment and ensure their working operational status. When laboratory space, 
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equipment and consumables are communal, it is good practice to appoint specific people to 
monitor stocks and set minimum threshold levels for key items. Similarly, establish 
procedures to ensure critical quality and safety activities are performed in line with good 
laboratory practice (GLP, discussed further in Section 4.2), for example, frequency of safety 
cabinet and incubator cleaning. Alongside this, having standard operating procedures (SOPs) 
with detailed methodologies helps maintain comparability between experiments and can 
serve as checklists, thereby maximising efficiency and eliminating errors.  
 
1.3 Create an efficient data trail  
Vast amounts of data can be produced from experimental procedures and analysis which 
require careful management. Whether on computers or in laboratory notebooks, do not 
simply name data/files by date or generic titles. This can cause difficulties in tracing specific 
data, potentially critical for intellectual property (IP) claims. Each experiment/analysis should 
receive a unique ID linking the scientist, paperwork and the electronic files containing both 
raw and analysed data. Electronic storage of completed notebooks is common industry 
practise, and where possible should be emulated in academia. Furthermore, and in addition to 
their requirements for IP, many publicly-funded research bodies have specific requirements 
for data management. Indeed, in light of the recent stimulus-triggered acquisition of 
pluripotency (STAP) controversy, data management is under greater scrutiny and it is likely 
that we may witness increased levels of internal auditing and data verification [1].  
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2. Ensure the data are scientifically robust  
Misleading ‘data’ can be very costly [1, 2]. Data robustness should be ensured through 
rigorous experimental design, appropriate use of statistical methods and familiarity with 
principles of key technologies. 
 
2.1 Invest time in planning and designing experiments 
Heed the words of G.J. Quarderer (Dow Chemical Co.), “Four to six weeks in the lab can 
save you an hour in the library” [3]. TERM experiments are expensive, can take weeks, even 
years, to complete, and involve complex biological systems. Yet in an effort to start 
collecting data, researchers sometimes rush into experimental work without due diligence and 
planning, often resulting in poorly designed experiments.  
 
Systematic methods such as factorial design of experiments (DOE) are valuable tools that can 
be used to design statistically relevant experiments, identify key variables and enhance both 
process and product understanding [4-7]. This places the emphasis on extensive planning and 
preparation prior to undertaking experimental work, and requires careful data analysis upon 
completion. The vast amount of useful data generated with minimal resource utilisation from 
a thorough DOE is far greater than the ‘one factor at a time’ (OFAT) approach, and likely to 
provide more value for TERM applications given the ability to identify relationships between 
factors at multiple levels. By taking the time upfront to plan, one can ensure that experiments 
are designed such that they are statistically valid with appropriate statistical tests employed to 
interrogate the data. No statistical ‘ingenuity’, however, can turn poor raw data into 
meaningful information. 
 
2.2 Source raw materials carefully 
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Maintaining supply of within-specification raw materials is essential for consistent 
manufacture, but may prove particularly problematic for biological materials. Reliance on 
animal-derived biological materials should be eliminated where possible, but without 
adequate replacements, many processes still rely on them (e.g. foetal bovine serum, FBS). 
Many constituents of FBS are undefined and even measurable elements vary between lots. 
With this in mind, and where applicable, it is good practice to test multiple raw material lots 
in order to identify critical material attributes (CMAs) relevant to desired outcomes, evaluate 
inherent variability in these, and establish limits/thresholds to form the basis of raw material 
specifications. The CMAs help guide towards defining the critical quality attributes (CQAs) 
of the product – product characteristics that must be within specified limits to ensure safety, 
identity, purity and potency, e.g. cell marker expression or proliferative capacity [8-10]. 
Subsequently, as raw material lots near depletion or expiry, tests should be performed to 
identify new lots that satisfy the CMA requirements, and in turn ensure the product CQAs are 
still met. Variation is inherent to biological materials but retaining as much control as 
possible over measurable factors can lead to more consistent, reproducible processes [9].  
 
The practice of reserving and buying specific lots applies to cell culture reagents generally, 
particularly those exhibiting biological variability such as MatrigelTM. For items which are 
manufactured by multiple suppliers, such as basal media and amino acid supplements, it is 
good practice to repeat-purchase from established suppliers [11]. Whilst this increases 
supply-chain risk, benefits arise in securing a consistently manufactured raw material and in 
developing long-term relationships with suppliers which may lead to discounted prices and 
preferential choice of stock. The selection process for supply of key reagents has to be 
rigorous and stringent (including due diligence of the supplier), and if it is necessary to 
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switch suppliers, it is imperative to determine whether potential new materials generate 
products that meet the CQAs. 
 
2.3 Understand the principles behind technologies 
Key instruments, such as fluorescence-based systems, have become ‘black-boxes’, requiring 
minimal user intervention and are commonly managed by a core facility. While this increases 
efficiency and accessibility, users can fail to appreciate the limitations or potential of the 
technology, including safety/quality critical protocols, due to a lack of understanding of the 
underlying principles on which the technology is based. Greater understanding of these 
principles will enrich data collection, facilitate reliable data interpretation, and enable the 
development of customisable applications. All of this can be achieved by working with 
experienced users/technicians. 
 
An example of this is flow cytometry (FC), which involves analysis of cell size, granularity 
and marker expression, whilst a similar technology, fluorescence activated cell sorting 
(FACS), sorts cells on these bases. TERM studies that employ FC often use only single 
colour antibody staining [12]. While effective in obtaining reproducible data, this method is 
cumbersome, requires large quantities of sample for analysis and, more critically, yields less 
information in comparison to multiparameter FC. User understanding should therefore 
include identification of appropriate isotype controls, instrument-relevant fluorophore 
combinations to allow for multiparameter analysis alongside accurate compensation and 
‘gating’ settings to distinguish cell types [13].  
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Understanding such principles can also improve device operation, and hence data reliability. 
For example, FACS does not sort cells, but rather charged droplets containing the cells; 
understanding this should promote diligence in charging plate maintenance, applying the 
correct charge and accurate positioning of the break-off point. Also, FC/FACS instruments 
are sensitive to atmospheric and temperature changes. Therefore, they require daily 
calibration, which should be factored into process design for clinical production.   
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3. Ensure the work has clinical relevance 
Although clinical translation can seem a distant prospect from some regions of the TERM 
landscape, increased impact, utility and adoption of the technology can be achieved by 
considering its clinical relevance. 
 
3.1 Align the research with appropriate ‘clinical pull’ 
Direct the research towards ‘clinical pull’ factors (Textbox1), which can be broadly split into 
three categories, namely, benefit to public health, reimbursement available to recoup 
investment and utility for clinicians. Indeed, addressing unmet clinical needs will likely be 
crucial for the translational success of regenerative therapies [14, 15]. Following benefits to 
public health, likelihood of reimbursement will be, in part, determined by predicted savings 
for healthcare providers/insurers based on current lifetime costs of treatment and care. Such 
lifetime savings for chronic conditions are currently attractive opportunities for regenerative 
medicines [15]. For example, although treatments for spinal cord injury are potentially 
expensive, they may attract substantial reimbursement due to savings on healthcare personnel 
time, through increased patient autonomy. On the other hand, acellular products may warrant 
limited reimbursement per item, but could provide advantages in terms of manufacturing 
costs, logistics and a simpler regulatory pathway, favouring a commercial plan to treat large 
numbers of patients [7]. The counterpart to clinical pull, ‘technology push’, can provide new 
engineering tools (e.g. CRISPR [16]) with strong IP that is attractive to investors, but without 
alignment to clinical pull there is little prospect of successful translation [14, 17-19].  
 
[Textbox 1] 
Clinical pull - Value to patients, clinicians, healthcare providers/insurers and industry can be 
broadly quantified by assessing: 
11 
 
 Demand for treatments (current patients; new patients/year; treatments/patient) 
 Utility for clinicians (likelihood of technology uptake in the clinic) 
  Potential quality of life improvements (e.g. as assessed by quality-adjusted life years 
[20-23]) 
  Lifetime savings versus costs of current care (number of procedures; expected 
lifetime with condition) 
 Manufacturing costs and reimbursement per treatment (profit) 
 
Often overlooked in terms of clinical pull is the need for enthusiasm amongst clinicians with 
respect to the utility of the technology, without which the product may never be adopted. 
Therefore, engagement with clinicians in order to assess their needs and wants is essential. 
Other benefits include feedback regarding therapeutic successes/failures, insights into the 
practicalities of administering therapies and clinical trial support/funding [24]. An example of 
this has been reported by researchers in the Moorfields Eye Hospital, with such arrangements 
providing competitive UK advantages [25]. 
 
3.2 Broaden the applicability of the research: increase chances of success 
Can the research serve as a platform technology applicable to other conditions? Platform 
technologies can enhance the translational utility of the research, providing multiple chances 
of a ‘hit’, reducing risk and conferring greater commercial value [15]. For example, drug/cell 
delivery systems could be developed with variants designed to administer different payloads, 
potentially treating a wide variety of pathologies. Indeed, companies such as Organogenesis, 
Athersys and Mesoblast have products which are approved for multiple indications, and this 
approach increases the chance of commercial viability [15]. However, resources should be 
focussed on a limited number of candidates at first, leaving the others in reserve. 
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3.3 Use predictive and relevant disease/injury models 
Among the most influential statisticians of his generation [26], George E.P. Box  wisely 
noted “all models are wrong, but some are useful” [27]. It is important to quickly assess the 
suitability of the safety and efficacy assays to avoid wasting resources on models known to 
lack predictive value. Indeed, it is increasingly recognised that many in vitro and in vivo 
models lack predictive utility [28, 29], with vast resources wasted on clinical trials that fail in 
spite of impressive preclinical data. With this in mind however, substantial inertia must be 
overcome for flawed models to be abandoned. These limitations can be addressed by 
employing a robust range of models to identify weaknesses early on, reducing the likelihood 
of failure when facing the heterogeneity of human patients [30]. In particular, many clinical 
trials employ patient stratification, as safety and efficacy frequently vary with patient age, 
sex, co-morbidity, genetics etc [31]. Preclinical testing can be similarly stratified by 
separately analysing multiple strains/species/cell lines, and perhaps co-morbidity models. In 
the coming era of personalised medicine, such data could identify the patients most likely to 
benefit from specific therapies, and spare those likely to be harmed. 
 
The problems with current preclinical testing offer rich opportunities for academia and 
industry, as TERM therapies will require new assays [32]. There are financial and ethical 
gains to be made by developing new models that address the 3Rs (replacement, reduction and 
refinement of animal models), with the ideal being the complete replacement of animal usage 
[33-35]. The greatest incentive to abandon unreliable systems will be the development of 
methods that reliably reproduce preclinical results at clinical trial. 
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4. Understand the regulations 
During the translation process, TERM researchers must address additional questions that not 
only satisfy basic science but also meet regulatory requirements to prime their research for 
translation. 
 
4.1. Define the product  
Region-specific regulatory bodies will have their own healthcare product definitions, which 
primarily differentiate between drug, medical device, advanced biologics or combination 
products [36]. In the United States, biologics are regulated by the Center for Biologics 
Evaluation and Research within the Food and Drug Administration (FDA). Within the 
European Medicines Agency (EMA) the equivalent is referred to as an advanced therapeutic 
medicinal product (ATMP) and these are regulated by the Committee for Advanced 
Therapies. Briefly, an ATMP is defined as a gene therapy, somatic cell therapy or tissue 
engineered product (EC 1394/2007). Stem cell-loaded scaffolds, drug-eluting meshes and 
chemical-secreting cells all fall within the combination product category [37]. Table 1 
describes product classifications as defined by regulatory agencies within Europe and USA.  
The initial step of classification can be challenging for TERM therapies. Their mode of action 
(MOA) cannot be defined as simply as traditional pharmaceuticals where MOA is a critical 
parameter used to determine assignment of classification. Particularly for combination 
products, establishing the primary MOA may be necessary for identifying appropriate 
approval pathways [38]. 
 
Product classification will dictate which regulatory route a product follows. Class I medical 
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devices have shorter routes to clinic with the rigor of regulation increasing with the 
complexity of the product [39, 40]. Further breakdown of the ATMP classification will 
significantly change the extent of regulation if the product meets both of the following 
criteria: a) ‘Minimally manipulated’ ATMPs undergo only non-substantial procedures such as 
centrifugation, cell separation and cryopreservation and b) ‘homologous use’ is when the 
ATMP is intended to perform the same function in the recipient as in the donor [41].  
Identifying the regulatory classification of the product can equip researchers with a 
framework of standards with which they can refer to during research, development and pre-
clinical stages to ensure two key authorisations are obtained: firstly, achieving approval to 
conduct human clinical trials and secondly gaining marketing authorisation [42] (Figure 1).  
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4.2 Ensure compliance with regulatory standards 
In order to meet good manufacturing practice (GMP) during later translation, there are 
standards that can be met at the early development stage, which will help build a robust 
portfolio of data to ease the transition towards clinical validation (Figure 1). Briefly discussed 
in Section 1.2, GLP should be exercised during early stages of translational research and 
beyond. GLP standards should be adhered to by any facility that carries out non-clinical 
safety testing with respect to human or environmental health. The standards ensure that the 
data gained from these studies are reliable and can be used for generating regulatory 
risk/safety assessments. GLP requires record keeping of lot numbers, raw data, appropriate 
test and control specimens, use of SOPs and evidence of robust study design. GMP is 
concerned with consistent production processes so that every batch of therapeutic will meet 
defined safety and efficacy standards. This will have a critical role at the later stages of 
product development where quality control becomes a requisite for market approval. Early 
compliance strategies to aid translation of the research include:  
 
1. Developing SOPs for all stages of production to promote consistency and to include 
quality assurance testing for characterization (21 CFR 610.14 2006) and contaminants (21 
CFR 610.13) [43, 44]. Determining the necessary standards for the product can be achieved 
by communication with regulatory authorities and organisations that establish standards for 
regulatory processes. The International Organisation for Standardisation, for example, can 
provide ISO standards for medical device quality management systems (ISO 13485:2003) 
and requirements for processing practices of medical products containing viable human cells 
(ISO 13022:2012). 
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2. Diligent sourcing of raw materials (from a regulatory perspective). Cell therapy products 
may involve the use of xenogeneic components such as FBS or gelatin. These may contain 
contaminants that cause bovine spongiform encephalopathy (BSE), and as a result regulatory 
bodies will ask for these materials to be sourced from animals that reside in countries 
certified to be free of BSE [45]. Non-clinical-grade cell sources or risk of infectious or 
genetic disease transmission may present significant hurdles for translation [42, 43]. 
3. Consider the current approval status for all materials. When developing a new product all 
materials used to construct that product should be assessed. This includes all reagents that 
come into contact with the product during manufacture. For example, building a combination 
product including cells and a biomaterial will require full approval of both components. 
4. Pre-clinical testing; develop in vitro and animal models to collect data output that is 
relevant from a regulatory standpoint including initial safety, efficacy, purity, dose response 
and mechanism of action in order to make the transition towards applying for approval as an 
investigational product more likely (Figure 1).  
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4.3 Identify the regulatory route to market and inform the regulators if necessary 
Traditionally, once a pharmaceutical product has been classified by regulators, it will follow 
a particular well-trodden route to approval for market authorisation. However, as the TERM 
field is still nascent, established approval routes are lacking, which opens up the opportunity 
to work closely with regulators to develop a suitable route for the product. 
 
The FDA approved its first tissue engineered product, ApligrafTM, in 1998. This product, 
containing viable human fibroblasts, was classified as a medical device and approved via the 
pre-market approval route for the treatment of chronic skin ulcers [46, 47]. Since then, many 
TERM products have emerged and may follow differing routes for approval (Table 2) due to 
regulatory learning and changes in the environment.  
 
For example, an important recent discussion for the reform of TERM regulation is the 
introduction of adaptive licensing. Japan is overhauling the regulatory landscape by 
introducing two new acts: one that covers regenerative medicine therapies without market 
approval, such as for research purposes and private practice within medical institutions (the 
Act on the Safety of Regenerative Medicine). The other regulates the market approval of 
regenerative medicine products for wider distribution (Pharmaceutical and Medical Devices 
Act) [48]. The latter act proposes a fast track system to enable time-constrained approval with 
exploratory clinical trial data that proves safety and ‘probable’ benefit. Extended post-market 
surveillance for prospective evidence gathering is allowed with subsequent adaptation to the 
original marketing authorisation. This overhaul has catalysed similar developments in Canada 
and the EU, where ‘‘conditional approval and staggered licensing” are being considered [49]. 
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Due to these many variations and continuous developments of regulatory pathways, it is 
encouraged to reach out to regulators at early stages to gain scientific advice. 
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5. Understand the implications for manufacture 
Identified by the UK’s national stock take of regenerative medicine as a significant challenge 
[50], the development of scalable, reproducible processes whilst retaining the product’s 
CQAs is critical for translational, and ultimately product success. Unlike conventional 
biopharmaceutical production, cells form the basis of TERM products. Product (cell) quality 
must therefore be maintained all the way through from donor isolation to patient delivery.  
 
5.1 Find out what’s relevant and measure it 
Improvement of production processes is achieved by obtaining a greater understanding of the 
product’s functional metrics. This understanding will arise through the development of novel 
measurement and characterisation technologies, providing opportunities for innovation and 
novel technology development. The progress of non-invasive live cell imaging and its 
utilisation as a process analytical tool is one such example of the integration of novel 
technologies to improve process understanding and consistency [51].  
 
Improved product understanding is driven by the need to maintain quality in inherently 
variable processes. It is imperative therefore that relevant functional metrics are identified, 
measured and that the range of allowable variation (as determined by preclinical and clinical 
trial data) is quantified, whilst maintaining product quality for each process step and ensuring 
that the extent of variation remains within these tolerances [6, 7]. Furthermore, the 
traceability or correlation to a common reference, along with method validation, completes 
the verification of process metrology. This will drive the development of robust control 
systems to ensure the process always remains in a ‘state of control’. 
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5.2 Consistently, consistently, consistently 
In regulator Health Canada’s Summary Basis of Decision for Remestemcel-L (Prochymal® - 
an allogeneic human mesenchymal stem cell therapy for acute Graft versus Host Disease), 
one word reverberated throughout: “consistently” [52]. From the document’s conclusions 
“…the Chemistry and Manufacturing information submitted for Prochymal has demonstrated 
that the drug substance and drug product can be consistently manufactured to meet the 
approved specifications”. It would be churlish of the translational researcher to ignore the fact 
that consistent manufacture is a prerequisite for regulatory approval. Developing consistent 
processes and repeatable procedures may require the adoption of chemically defined xeno-
free production and implementing methods aimed at identifying and reducing variation in 
biological source material. Investing in consistent manufacture and developing repeatable 
procedures can provide economic value, for example by reducing process deviation (and 
therefore the risk of batch failure) and increasing production capacity. It demonstrates a ‘state 
of control’ and a high degree of product understanding, improving the likelihood of 
regulatory approval.  
 
It is also worth noting that whilst consistency is paramount to any TERM manufacturing 
process, achieving this can be extremely difficult, particularly for inherently variable 
bioprocesses such as autologous processes where donor material will differ from patient to 
patient [53], as opposed to allogeneic processes where there is a degree of control with 
respect to biological starting material. Whilst it is unfeasible to eliminate variation entirely, 
understanding the sources of variation and identifying strategies to minimise these is critical 
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and may result in a situation where differences in the product do not affect patient outcome 
[53]. 
 
5.3 Consider scale from the outset 
In the pharmaceutical/biopharmaceutical industries, efficiency and productivity typically 
plummet when processes are transferred from laboratory to industrial scale [54]. As part of 
due diligence and risk management, scalability should be considered from the outset, 
including an early assessment of cost of goods and supply chain risks.  
 
To avoid technical issues associated with scale-up, small-scale models that demonstrate 
comparability with larger-scale systems should be adopted where possible. For example, 
small-scale stirred-tank bioreactor platforms are more reliable predictors of large-scale 
performance than traditional shake-flask models, reducing time to market and cost of goods 
[55]. Moreover, translational researchers should employ quality tools such as risk 
assessments and process maps to break down each process step to its constituent components 
and ensure that each process platform is scalable, and identify what process steps, if any, can 
be eliminated entirely or replaced with an alternative, more readily scalable step. Examples of 
these quality tools include FMEAs (Failure Mode and Effect Analysis), Ishikawa Diagrams 
and Pareto Charts [6]. The use of quality tools, for example, may identify reagents or 
consumables that are not suitable for scaled manufacture. As described above (Section 2.2) 
raw materials must be selected and sourced carefully in order to minimise variability. Where 
possible, alternatives to process critical components (i.e. surface-coatings, growth factors 
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etc.) should be identified and if no alternative is available, the risk should be acknowledged 
and mitigated, for example, by securing future supply in the event of large-scale production.   
 
Additionally, the relevant business processes should be mapped out and it should be 
determined which particular manufacturing processes will be constrained by economic and 
value-chain drivers. This may reveal insurmountable cost of goods arising from impracticable 
scaled production, allowing for alternative options to be considered. It is worth noting that the 
production and business processes will vary significantly depending on the final product. For 
example, a product such as autologous CD34+ transplantation which involves only the 
enrichment of a patient’s cells will require a different manufacturing process to an autologous 
process which requires direct reprogramming and subsequent differentiation of the patient’s 
starting material. This also has regulatory implications as discussed in Section 4.1, 
particularly where a product may or may not be considered to be ‘minimally manipulated’.  
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6. Manage the commercial potential of the research 
Clinical translation of TERM therapies depends on successful project management to develop 
a product that meets both clinical need and safety and regulatory requirements. Additionally, 
effective IP management is vital to deliver a viable product that offers an investable 
proposition to those involved. Technology transfer offices (TTOs) often provide expert, free 
advice to ECRs on whether research is protectable by IP and how it can be translated. 
 
6.1 Protect the idea to establish commercial value 
IP protection secures an idea’s exclusivity and indicates value to potential investors. Deciding 
which aspects of an idea are suitable for IP protection, and who is the rightful owner of an 
invention, depends on both contributions to the conception and execution of an idea, as well 
as contractual agreements at individual institutions (Textbox 2). To maximise the impact of 
research and commercial value across several fields, ECRs should identify translational IP 
space, and appreciate its breadth. For example, one should consider whether the concept 
could be developed as a platform technology, with multiple potential applications (e.g. 
platforms applicable to various patient-specific autologous cells) [56].  
 
Researchers should also consider whether to seek protection in the UK, Europe, US or 
worldwide, and once protected, they can choose whether to self-develop (in-house or through 
academic/industrial collaborations), or to assign IP to another party. TTOs can assist with 
writing IP applications and often fund a bid for one year’s protection, during which proof-of-
concept research and market value investigations can be undertaken. A full application may 
then be funded by the inventors, TTO, or other backers; however without funding, protection 
ends after one year, so sourcing funding for full IP protection is a crucial translational hurdle.   
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Academic ECRs should also consider the increasing pressure to disseminate research and 
offset this with the consequences of invalidating IP by revealing prior art. For collaborative 
research, describing information as proprietary or signing confidential disclosure agreements 
(CDAs) can safeguard ideas prior to IP applications.  
 
 
 [Textbox 2]_________________________________________________________________ 
Is it patentable? 
To be patentable, ideas must be novel, not obvious, and useful [57]. This could include a new 
use for a pre-existing idea. 
Who is the inventor? 
The person conceiving the idea, or a novel step in the fabrication of the idea [57]. People 
instructed to perform experiments/research/development are not inventors; they have 
“reduced to practice” a novel idea. The inventor is often not the owner of the idea; the 
employer is usually the owner.  
---------------------------------------------------------------------------------------------------------- 
 
6.2 Market the concept and develop a network 
Successful project management (described in Section 1) should allow ECRs to identify, liaise 
and engage with appropriate bodies to develop a translational pathway. This may involve 
forming a ‘spin out’ or joint venture, which allows the inventor to retain some control over IP 
commercialization. Alternatively, IP can be sold or licenced to third parties through 
technology licencing agreements; however, the inventor’s involvement usually ends here. 
Building a personal network with those in relevant fields will enable both the development of 
one’s reputation and allow for the identification of collaborators who can aid translation. 
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Forming collaborations with those experienced in scale up, automation or other 
manufacturing issues can help accelerate the transition to market. Importantly, national and 
international consortia facilitating translation from research concept to commercialisation 
through collaborations are becoming more common, providing straightforward access to a 
range of expertise [58, 59].  
 
6.3 Leverage funding 
Funding will be required throughout stages of the translation process (Figure 3). Research 
councils and charities commonly fund proof-of-concept research, but have varying eligibility 
regarding funds for later stage commercialisation such as Phase I through Phase III trials 
[60]. Instead, alternative funding sources such as business angels, key opinion leaders or 
commercialisation seed funding schemes (Table 3) can be accessed for support. Eligibility 
criteria for these highly competitive schemes vary, often requiring matched funding from an 
industrial collaborator (which can be limited to small/medium enterprises, SMEs), but 
funders may offer additional support during the application process and post-award. 
Preparing bids is time-consuming, so try to get early notice via automated notifications/alerts 
(e.g. Google alerts, mailing lists) and leverage collaborators’ knowledge of funding trends 
and requirements to save both time and money. 
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Conclusion 
Having strategically designed the concept with clinical relevance, manufacturing and 
regulatory hurdles in mind, validated the scientific worth, protected the idea, and sourced 
appropriate funding and collaborators, translation into a commercial product is feasible. 
Although navigating through the translational landscape may seem daunting, we suggest that 
ECRs can increase their chances of success by tactically planning their research to address 
these common pitfalls early, minimising the chances of having to reiterate a design step later 
on in the commercialisation process.   
 
Future perspective 
Clinical and commercial failures in recent years have reinforced the need for the translation 
of TERM therapies. The industry is therefore entering a critical phase which can no longer 
rely on potential, but is expected to deliver efficacious, cost-effective products. Whilst this 
presents a significant challenge, the TERM industry is ideally positioned to capitalise on 
recent clinical success (e.g. T-cell immunotherapy) amidst a backdrop of renewed 
government/state investment (e.g. Cell Therapy Catapult, Centre for Commercialization of 
Regenerative Medicine). What imbues the greatest confidence of success, however, is the 
emergence of a generation of highly trained, committed, translationally-focussed ECRs.  
 
Although faced with an uncertain regulatory/reimbursement landscape and complex 
scientific/technical obstacles, global recognition of the importance of translation will ensure 
that translational ECRs are given the appropriate authority to play a central role in the 
realisation of TERM therapies. We believe translational ECRs will rise to the challenge, 
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learning from mistakes of the past, adopting best practices from closely aligned industries and 
developing innovative solutions to TERM-specific issues in a pre-competitive environment.     
 
Executive summary 
As translational ECRs in TERM, we have come to realise that the process of translation can 
be intricate, exceptionally resource consuming and prone to hidden obstacles. We have 
therefore compiled ‘tips and tricks’, based on our own experience and research that facilitate 
translation and will improve the chances of successful product development. 
 
Manage the research effectively 
 Utilise project management tools and divide the research into work packages with 
clear milestones and deliverables. Effective research management also includes day-
to-day planning, mapping out the experimental process and identifying high risk areas 
and ways of mitigating these. 
 
Ensure the data are scientifically robust 
 Experiments in TERM are resource heavy. Take time and care in planning 
experiments and implement systematic methods such as Design of Experiments. 
Source raw materials carefully and ensure that the principles of any technology, assay 
or technique are well understood to ensure maximum output of reliable and robust 
data. 
 
Ensure the work has clinical relevance 
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 To increase chances of clinical and commercial success, research should be aligned 
with appropriate clinical pull, and where possible developed as platform technologies. 
In addition, many current assays are unreliable, or unsuitable for testing TERM 
therapies, but these shortcomings provide rich opportunities for the development of 
new, TERM-relevant models with genuine predictive utility.  
 
Understand the regulations 
 Identify early on in the research programme the regulatory classification of the 
potential product to provide a framework of standards which can be referred to. Build 
compliance of regulatory standards into the process, and when necessary, be prepared 
to engage and inform the regulator. 
 
Understand the implications for manufacture  
 Relevant functional metrics, with associated tolerances, need to be identified and 
quantified to improve process and product understanding. The pursuit of consistency 
in manufacture is paramount and efforts must be made to avoid or minimise source of 
variation. Scalability should be considered from the outset with a focus not only on 
the technical challenges but also cost of goods and supply chain issues associated with 
scaled production. 
 
Commercialise the research 
 IP protection is generally necessary to demonstrate commercial value. Effective 
partnerships and collaborations will accelerate commercialisation and de-risk the 
venture for potential investors and funders to invest. Develop an effective funding 
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strategy, stratifying funding sources if necessary and leveraging funds from one 
source with another.  
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Any substance or combination of substances presented as having 
properties for treating or preventing disease in human beings; or 
b) Any substance or combination of substances which may be 
used in or administered to human beings either with a view to 
restoring, correcting or modifying physiological functions by 
exerting a pharmacological, immunological or metabolic action, 
or to making a medical diagnosis. [Directive 2001/83/EC, Article 
1.2] 
a) Articles recognized in the official United States 
Pharmacopoeia, official Homoeopathic Pharmacopoeia of the 
United States, or official national formulary, or any supplement 
to any of them; and b) articles intended for use in the diagnosis, 
cure, mitigation, treatment, or prevention of disease in man or 
other animals; and c) articles (other than food) intended to affect 
the structure or any function of the body of man or other animals; 
and d) articles intended for use as a component of any article 
specified in Clause a), b), or c). [21 USC 321(g)(1)] 
Committee for 
Medicinal 
Products for 
Human use 
(CHMP) 
 
 
 
 
Center for Drug 
Evaluation and 
Research 
(CDER) 
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Consists of either: A gene therapy medicinal product as defined 
in Part IV of Annex I to Directive 2001/83/EC, — a somatic cell 
therapy medicinal product as defined in Part IV of Annex I to 
Directive 2001/83/EC, — a tissue engineered product as defined 
in (1(d) (EC) No. 1394/2007). 
Biological products include vaccines, blood and blood 
components, allergenics, somatic cells, gene therapy, tissues, and 
recombinant therapeutic proteins. Biologics can be composed of 
sugars, proteins, or nucleic acids or complex combinations of 
these substances, or may be living entities such as cells and 
tissues.  
Committee for 
Advanced 
Therapies 
(CAT) 
 
Center for 
Biologics 
Evaluation and 
Research 
(CBER) 
M
ed
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al
 D
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ic
e 
Any instrument or other article to be used in human beings for 
the purpose of:  
a) diagnosis, prevention, monitoring, treatment or alleviation of 
disease or compensation for an injury or handicap, b) 
investigation, replacement or modification of the anatomy or of a 
physiological process, c) control of conception, and which does 
not achieve its principal intended action in or on the human body 
by pharmacological, immunological or metabolic means, but 
which may be assisted in its function by such means. [Directive 
93/42/EEC, article 1.2(a)] 90/385/EEC 
An instrument or related article which is: 
- intended for use in the diagnosis of disease or other conditions, 
or in the cure, mitigation, treatment, or prevention of disease, in 
man or other animals, or 
- intended to affect the structure or any function of the body of 
man or other animals, and which does not achieve its primary 
intended purposes through chemical action within or on the body 
of man or other animals and which is not dependent upon being 
metabolized for the achievement of any of its primary intended 
purposes." 
21 USC 321(h) 
Notified Body 
(NB) 
 
Center for 
Devices and 
Radiological 
Health (CDRH) 
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Table 1. Healthcare product definitions. Classifications for healthcare products are listed 
here as described by regulatory bodies within Europe (EMA, red) and USA (FDA, blue). 
Adapted from [61]. *For complete definitions refer to the associated regulatory directive. 
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‘Combined advanced therapy medicinal product’ must 
incorporate, as an integral part of the product, one or more 
medical devices within the meaning of Article 1(2)(a) of 
Directive 93/42/EEC or one or more active implantable medical 
devices within the meaning of Article 1(2)(c) of Directive 
90/385/EEC, and — its cellular or tissue part must contain viable 
cells or tissues, or — its cellular or tissue part containing non-
viable cells or tissues must be liable to act upon the human body 
with action that can be considered as primary to that of the 
devices referred to. (2001/83/EC) or tissue engineered product 
(1(d) (EC) No. 1394/2007). 
A product comprised of two or more regulated components 
drug/device/biologic that are combined or intended to be used as 
single entity. 21 CFR 3.2(e) 
EMA/CAT-NB 
Collaboration 
Group 
 
Office of 
Combination 
Products 
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Table 2. Regulatory routes for selected TERM products from the European and 
American market.  
  
Product Description  Regulatory Route 
Prochymal Human mesenchymal stem cells 
for treatment of GVHD. 
Conditional Approval (Canada, 2012) 
Expanded Access (USA 2008) 
Holoclar 
(EMA/786996/2014) 
Limbal epithelial stem cell 
therapy 
Conditional Approval (EU, 2015) 
OP-1 Putty Bovine collagen graft with 
rhBMP-7 
Humanitarian Device Exemption 
(USA, 2004) 
Carticel Autologous cultured 
chondrocytes for cartilage defects 
Biologics license (USA, 1997) 
MySkin Autologous human keratinocytes 
for burns 
Unlicensed medicinal product (UK) 
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Table 3. Examples of funding sources used to commercialise research. Funders are categorised based on who the funds are linked to, the location of 
funded research, the type of application process, the value of the award and the phase of the translational pathway that the award funds.   
 
 
Funding source Who is it linked 
to? 
Where is it 
based? 
How to 
apply 
Value Project stage    Notes 
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Research Councils           Varies    * Individual research councils have own eligibility/criteria 
Therapy area charities           Varies    Individual therapy area charities have own eligibility criteria 
National competitions / 
Entrepreneur schemes (e.g. 
Biotechnology YES) 
          £2,500    Eligibility: Non business ECR team 
Cell Therapy Catapult 
 
          Varies, facilities     
Impact acceleration           Varies    Usually PI must have existing grant, linked to host 
institution 
Innovate UK (formally TSB) 
 
          £5,000 - £10 
million 
   Eligibility: must be UK based company linked 
Venture capital           Varies    Requires contractual agreement with set milestones 
Centre for Commercialization of 
Regenerative Medicine (CCRM) 
          Facility based    Based in Canada, eligibility varies 
California Institute for 
Regenerative Medicine (CIRM) 
          Varies    Must be linked to California, awards over $10 million  
Citizens’ Innovation Fund            
Varies 
   Currently limited to France, £15,000 per person  tax free 
general public investment in scheme 
Horizon 2020 
 
 
          Varies    Linked to academic institution 
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Figure 1. Overview of regulatory approvals and standards along the pathway to 
translation in Europe and USA. A general comparison of the regulatory process for a 
medical device and a biologic/advanced therapy medicinal product in Europe (grey, italics) 
and the USA. Regulatory standards to be met can be found in the example directives listed. 
The changing regulatory landscape for TERM therapies can include other routes not depicted 
here such as fast track pathways that have recently been unveiled in Japan (see Section 4.3). 
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Figure 2: Translational Research Pipeline. The schematic depicts funding stages 
throughout translation and associated issues to consider when designing research at each 
stage.    
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